LV end systolic volume, indexed (mL/m2 )-2.4-5.1 LV end diastolic volume, indexed (mL/m2)-5.7-10.0 *Baseline is referred to as start of HOPE-2 study, changes in medians are shown; 3-year timepoint on ...
Capricor Therapeutics Inc. (NASDAQ:CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock ...
In male patients with DMD, treatment with deramiocel reduced upper limb function deterioration compared with placebo. The Food and Drug Administration (FDA) has granted Priority Review to the ...
-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) ...
Tuesday, Capricor Therapeutics Inc (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company, for the commercialization and distribution in ...
–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, ...
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance ...
Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophy BLA supported by positive pivotal HOPE-3 Phase 3 results, ...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results